Sienna Biopharmaceuticals, Inc. (SNNA) Financial Statements (2024 and earlier)

Company Profile

Business Address 30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2019
MRQ
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 48,526,00074,467,000
Cash and cash equivalents 48,526,00074,467,000
Restricted cash and investments 181,000181,000
Other undisclosed current assets 1,705,0002,698,000
Total current assets: 50,412,00077,346,000
Noncurrent Assets
Property, plant and equipment 311,000432,000
Intangible assets, net (including goodwill) 10,989,00011,472,000
Goodwill 10,989,00011,472,000
Other undisclosed noncurrent assets 45,594,00047,597,000
Total noncurrent assets: 56,894,00059,501,000
TOTAL ASSETS: 107,306,000136,847,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 10,636,0008,010,000
Employee-related liabilities 3,057,0002,646,000
Accounts payable 2,792,0002,357,000
Accrued liabilities 4,787,0003,007,000
Business combination, contingent consideration, liability 13,500,000 
Other undisclosed current liabilities 213,000231,000
Total current liabilities: 24,349,0008,241,000
Noncurrent Liabilities
Long-term debt and lease obligation 30,125,000 
Long-term debt, excluding current maturities 30,125,000 
Liabilities, other than long-term debt 26,203,00033,864,000
Deferred tax liabilities, net10,503,00010,964,000
Business combination, contingent consideration, liability 15,700,00022,900,000
Other undisclosed noncurrent liabilities 48,0003,543,000
Total noncurrent liabilities: 56,376,00037,407,000
Total liabilities: 80,725,00045,648,000
Equity
Equity, attributable to parent 26,581,00091,199,000
Common stock  2,000
Additional paid in capital 182,750,000171,724,000
Accumulated other comprehensive income 3,199,0005,370,000
Accumulated deficit (159,368,000)(85,897,000)
Total equity: 26,581,00091,199,000
TOTAL LIABILITIES AND EQUITY: 107,306,000136,847,000

Income Statement (P&L) (USD)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses (76,498,000)(48,571,000)
Operating loss: (76,498,000)(48,571,000)
Nonoperating income (expense) 3,027,000(2,264,000)
Loss from continuing operations before income taxes: (73,471,000)(50,835,000)
Income tax benefit  290,000
Loss from continuing operations: (73,471,000)(50,545,000)
Loss before gain (loss) on sale of properties: (73,471,000)(50,545,000)
Net loss available to common stockholders, diluted: (73,471,000)(50,545,000)

Comprehensive Income (USD)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss: (73,471,000)(50,545,000)
Other comprehensive loss (2,171,000) 
Comprehensive loss: (75,642,000)(50,545,000)
Other undisclosed comprehensive income, net of tax, attributable to parent  5,736,000
Comprehensive loss, net of tax, attributable to parent: (75,642,000)(44,809,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: